| Name | Title | Contact Details |
|---|
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company`s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.
Catalyst Nutraceuticals is a family-owned and operated business that specializes in custom manufacturing and formulation of dietary supplements for performance nutrition and wellness brands.
Dyancon is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Indago is developing smart surgical tools that enable physicians to focus on healthcare, not hardware. Our mission: to create the OR of the future.
97250 Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City.